Cautionary statement regarding forward-looking statements

This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D ‘Risk factors’ in the Group's Annual Report on Form 20-F for the full year (FY) 2022, and any impacts of the COVID-19 pandemic. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in the Q1 2023 earnings release and Annual Report on Form 20-F for FY 2022.

All guidance, outlooks, ambitions and expectations should be read together with the Guidance, assumptions and cautionary statements in GSK’s Q1 2023 earnings release and the 2022 Annual Report.

Basis of preparation: GSK satisfied the formal criteria according to IFRS 5 for treating Consumer Healthcare as a ‘Discontinued operation’ effective from 30 June 2022. On 18 July 2022, GSK plc separated its Consumer Healthcare business from the GSK Group to form Haleon, an independent listed company. Comparative figures have been restated on a consistent basis. Earnings per share, Adjusted earnings per share and Dividends per share have been adjusted to reflect the GSK Share Consolidation on 18 July 2022.
A focused global biopharma company with bold ambitions

Priorities: Innovation, Performance and Trust

Ambition and Purpose
To unite science, technology, and talent to get ahead of disease together

Growth
Highly attractive medium-term target for sales and adjusted operating profit growth of >5% and >10% CAGR for 2021-26

Flexibility
Strengthened balance sheet, creating new flexibility to invest in growth and innovation
Full year 2022
Delivered a landmark year

Step change in commercial execution with growth across the portfolio:
• Specialty Medicines +29%
• Vaccines +11%

Prioritised investment and cost control support strong operating profit and EPS growth

R&D delivery and business development support future growth

<table>
<thead>
<tr>
<th></th>
<th>Turnover</th>
<th>Adj. operating profit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>£29.3bn</td>
<td>£8.2bn</td>
</tr>
<tr>
<td>% growth</td>
<td>+13%</td>
<td>+14%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Adj. EPS</th>
<th>Free cash flow</th>
</tr>
</thead>
<tbody>
<tr>
<td>% growth</td>
<td>+15%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>139.7p</td>
<td>£3.3bn</td>
</tr>
</tbody>
</table>

2022 dividend
61.25p

All references to percentage growth during presentation provided at CER
Performance: Vaccines +11%
Double digit sales growth driven by *Shingrix* and meningitis

- One of the broadest portfolios of vaccines across all stages of life: >20 vaccines including meningitis, shingles, flu, polio, measles and many more

- *Shingrix* delivers record £3bn sales: driven by US and roll out in other markets (inc. Germany and China). Confident in doubling *Shingrix* sales by 2026

- Meningitis sales over £1bn: *Bexsero* and *Menveo* achieve combined sales of £1.1bn. Expect to double sales of meningitis business by 2031
Performance: Specialty Medicines +29%
Double digit sales growth driven by HIV, Nucala and Benlysta

- HIV sales £5.7bn +12%: driven by two drug regimens and long-acting injectable portfolio
- New HIV product sales £2.5bn: 43% of HIV portfolio
- Other speciality medicines performing strongly
  - Nucala £1.4bn +18%
  - Benlysta £1.1bn +20%
- Xevudy, our COVID-19 treatment, sales £2.3bn: One of world’s biggest selling COVID treatments

Momentum building across HIV portfolio

Performance:
Specialty Medicines +29%
Double digit sales growth driven by HIV, Nucala and Benlysta
Evolving portfolio
Shift to Vaccines and Speciality Medicines and newer growth drivers

Specialty Medicines and Vaccines

Sales (£bn)

- HIV
- Other Specialty Medicines
- Vaccines
- % GSK sales

2017 2018 2019 2020 2021 2022
0 5 10 15 20
0 10 20 30 40 50 60 70
46% 50% 55% 58% 58% 62%
0% 10% 20% 30% 40% 50% 60% 70%
Evolving portfolio
Shift to Vaccines and Speciality Medicines and newer growth drivers

Progress of priority growth drivers

<table>
<thead>
<tr>
<th>Year</th>
<th>Shingrix</th>
<th>Meningitis</th>
<th>Trelegy</th>
<th>Nucala</th>
<th>Benlysta</th>
<th>Oncology</th>
<th>HIV 2DRs</th>
<th>cabotegravir</th>
<th>% GSK sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>7%</td>
<td>13%</td>
<td>22%</td>
<td>28%</td>
<td>33%</td>
<td>42%</td>
<td>24%</td>
<td>10%</td>
<td>31%</td>
</tr>
<tr>
<td>2018</td>
<td>13%</td>
<td>22%</td>
<td>28%</td>
<td>33%</td>
<td>42%</td>
<td>7%</td>
<td>19%</td>
<td>16%</td>
<td>36%</td>
</tr>
<tr>
<td>2019</td>
<td>22%</td>
<td>28%</td>
<td>33%</td>
<td>42%</td>
<td>7%</td>
<td>13%</td>
<td>22%</td>
<td>18%</td>
<td>24%</td>
</tr>
<tr>
<td>2020</td>
<td>28%</td>
<td>33%</td>
<td>42%</td>
<td>7%</td>
<td>13%</td>
<td>22%</td>
<td>22%</td>
<td>20%</td>
<td>30%</td>
</tr>
<tr>
<td>2021</td>
<td>33%</td>
<td>42%</td>
<td>7%</td>
<td>13%</td>
<td>22%</td>
<td>22%</td>
<td>20%</td>
<td>23%</td>
<td>26%</td>
</tr>
<tr>
<td>2022</td>
<td>42%</td>
<td>7%</td>
<td>13%</td>
<td>22%</td>
<td>28%</td>
<td>33%</td>
<td>42%</td>
<td>32%</td>
<td>34%</td>
</tr>
</tbody>
</table>
A focused biopharma company
Uniting science, technology and talent to get ahead of disease together

Four focused therapeutic areas

Two thirds of our development portfolio comes from infectious diseases and HIV

Infectious diseases  HIV  Immunology/respiratory  Oncology
Pipeline progress
Continued momentum in 2022 and into 2023

Infectious diseases

- Positive phase 3 data and regulatory submissions for RSV older adults vaccine
- Acquisition of Affinivax
- Positive phase 3 data for MenABCWY vaccine
- Positive phase 2b data for Bepirovirsen
- Positive phase 3 data for Gepotidacin
- Proposed exclusive licence with Scynexis for Brexafemme
- Exclusive licence with Spero Therapeutics LLC for tebipenem

HIV

- Launch of Apretude
- US approval of Cabenuva for two-monthly dosing and positive phase 3b data
- Continue to progress early phase, next-generation long-acting

Immunology/respiratory

- Depemokimab phase 3 continues
- Proposed acquisition of Bellus Health
- Nucala COPD phase 3 continues

Oncology

- Acquisition of Sierra Oncology
- Several positive data readouts for Jemperli
Pipeline progress and momentum
Continued momentum in 2022 and into 2023

Infectious diseases

- Positive phase 3 data and regulatory submissions for RSV older adults vaccine
- Acquisition of Affinivax
- Positive phase 3 data for MenABCWY vaccine
- Positive phase 2b data for Bepirovirsen
- Positive phase 3 data for Gepotidacin
- Proposed exclusive licence with Scynexis for Brexafemme
- Exclusive licence with Spero Therapeutics LLC for tebipenem

HIV

- Launch of Apretude
- US approval of Cabenuva for two-monthly dosing and positive phase 3b data
- Continue to progress early phase, next-generation long-acting

Immunology/respiratory

- Depemokimab phase 3 continues
- Proposed acquisition of Bellus Health
- Nucala COPD phase 3 continues

Oncology

- Acquisition of Sierra Oncology
- Several positive data readouts for Jemperli
Pipeline progress and momentum
Continued momentum in 2022 and into 2023

**Infectious diseases**
- Positive phase 3 data and regulatory submissions for RSV older adults vaccine
- Acquisition of Affinivax
- Positive phase 3 data for MenABCWY vaccine
- Positive phase 2b data for Bepirovirsen
- Positive phase 3 data for Gepotidacin
- Proposed exclusive licence with Scynexis for Brexafemme
- Exclusive licence with Spero Therapeutics LLC for tebipenem

**HIV**
- Launch of Apretude
- US approval of Cabenuva for two-monthly dosing and positive phase 3b data
- Continue to progress early phase, next-generation long-acting

**Immunology/respiratory**
- Depemokimab phase 3 continues
- Proposed acquisition of Bellus Health
- Nucala COPD phase 3 continues

**Oncology**
- Acquisition of Sierra Oncology
- Several positive data readouts for Jemperli
Pipeline progress and momentum
Continued momentum in 2022 and into 2023

Infectious diseases

- Positive phase 3 data and regulatory submissions for RSV older adults vaccine
- Acquisition of Affinivax
- Positive phase 3 data for MenABCWY vaccine
- Positive phase 2b data for Bepirovirsen
- Positive phase 3 data for Gepotidacin
- Proposed exclusive licence with Scynexis for Brexafemme
- Exclusive licence with Spero Therapeutics LLC for tebipenem

HIV

- Launch of Apretude
- US approval of Cabenuva for two-monthly dosing and positive phase 3b data
- Continue to progress early phase, next-generation long-acting

Immunology/respiratory

- Depemokimab phase 3 continues
- Proposed acquisition of Bellus Health
- Nucala COPD phase 3 continues

Oncology

- Acquisition of Sierra Oncology
- Several positive data readouts for Jemperli
Building Trust: reducing risk and delivering positive social impact
For health impact, shareholder returns and thriving people

Six priority areas of responsible business

- Access
- Global health and health security
- Environment
- Diversity, equity and inclusion
- Product governance
- Ethical standards

1st position in the Access to Medicines Index for 8th consecutive year and a leading approach in AMR

2nd ranking in S&P Corporate Responsibility Assessment in pharmaceutical sector

13% cut in carbon emissions across value chain against 2020 baseline
A focused global biopharma company with bold ambitions

Priorities: Innovation, Performance and Trust

Ambition and Purpose
To unite science, technology, and talent to get ahead of disease together

Growth
Highly attractive medium-term target for sales and adjusted operating profit growth of >5% and >10% CAGR for 2021-26

Flexibility
Strengthened balance sheet, creating new flexibility to invest in growth and innovation